Antigen presentation by autoreactive proteolipid protein peptide-specific T cell clones from chronic progressive multiple sclerosis patients: roles of co-stimulatory B7 molecules and IL-12.
To assess the role of T cell antigen (Ag) presentation in multiple sclerosis (MS), proteolipid protein (PLP) peptide reactive CD4+ T cell clones (TCCs) from MS patients and normal subjects were studied. TCCs derived from chronic progressive (CP) MS patients were able to proliferate and secret cytokines in response to PLP peptide stimulation in the absence of professional antigen presenting cells (APCs), suggesting that these T cells can simultaneously present and respond to Ags. However, they did not respond to total PLP protein, suggesting that PLP-peptide TCCs were unable to process and present the whole PLP molecule. The ability of the different TCCs to act as APCs in response to Ag stimulation did not correlate with expression of HLA-class II molecules. However, the degree of expression of B7-1 and B7-2 co-stimulatory molecules showed a significant correlation with APC capacity. Furthermore, a combination of anti-B7-1 and anti-B7-2 mAbs effectively inhibited proliferative responses as well as secretion of IL-10, IFN gamma and TGF beta induced by antigen presenting T cells. By contrast, IL-4 secretion was not affected. Finally, IL-12 significantly enhanced the efficiency of T cell Ag presentation by a pathway independent of Ag processing, suggesting that IL-12 might act as an additional co-stimulatory signal for T cell activation during T-T cell interactions. Together, these observations suggest that Ag presentation by T cells might amplify and perpetuate an autoimmune response previously initiated by professional APCs. These properties may account for progression of MS into a CP phase.
Correale
J
J
Department of Neurology, USC School of Medicine, Los Angeles 90033, USA. correale@hsc.usc.edu
McMillan
M
M
Li
S
S
McCarthy
K
K
Le
T
T
Weiner
L P
LP
D000328:Adult; D000368:Aged; D019138:Antibodies, Blocking / Q000494:pharmacology; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D017951:Antigen Presentation / Q000187:drug effects / Q000276:immunology*; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology*; D002455:Cell Division / Q000276:immunology; D002999:Clone Cells / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology*; D018991:Myelin Proteolipid Protein / Q000276:immunology* / Q000494:pharmacology; D009422:Nervous System Diseases / Q000276:immunology; D010455:Peptides / Q000276:immunology / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D011863:Radioimmunoassay; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D018122:B7-1 Antigen; D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D018991:Myelin Proteolipid Protein; D010455:Peptides; D012333:RNA, Messenger; D018664:Interleukin-12